Skip to content
Review Open access

Making Broad Evidence Synthesis Feasible: An LLM Screening Agent for Meta-Analyses Applied To Suicide Prevention

Aug 2026 · medRxiv · 0 citations
Medicine

TL;DR

To develop and validate ScreenAgent, a large language model (LLM) agent for title and abstract screening, and a review-specific method for prospectively estimating screening performance, which identified nearly all eligible studies with human-level reliability for a fraction of a US cent per record while keeping human reviewers as the final arbiters.

Abstract

Importance. Systematic reviews and meta-analyses inform suicide-prevention policy and practice, but broad database searches are difficult to screen manually. This limits capture of upstream interventions, such as economic policies, with indirect effects on suicide. Reliable automated screening could make broader and more comprehensive evidence syntheses feasible. Objective. To develop and validate ScreenAgent, a large language model (LLM) agent for title and abstract screening, and a review-specific method for prospectively estimating screening performance. Design, Setting, and Participants. ScreenAgent was validated internally on a prospective meta-analysis, and externally on two published systematic reviews. The correct include and exclude decisions followed standard systematic-review screening methodology. Exposures. ScreenAgent, an LLM agent returning structured include-or-exclude decisions. Records it marked for inclusion were re-checked by a second, cascade pass using a higher-effort LLM. For the external reviews, the agent's prompt was tuned automatically on a small set of labeled examples. Main Outcomes and Measures. We calculated sensitivity, specificity, workload reduction (the percentage of records removed from human review), and agent-versus-human reliability via Cohen kappa. Sensitivity was estimated by direct comparison (internal) and 5-fold cross-validation (external). Results. In the internal validation, ScreenAgent identified 43 of 44 eligible studies (sensitivity 97.7%; 95% CI, 88.2%-99.6%) with a generic prompt applied without any review-specific optimization, specificity 98.0%, and a measured full-corpus workload reduction of 99.4%. The cost was $855.91 for the full 201,064-record corpus (0.43 US cents per record). Agent-versus-human-consensus agreement exceeded human-versus-human agreement (Cohen kappa 0.75 vs 0.64; percent agreement 97.3% vs 95.4%). For two external validation studies, automatic tuning resulted in a cross-validated sensitivity of 95.9% (95% CI, 90.0%-98.4%) and 97.4% (90.9%-99.3%), with workload reductions of 97.4% and 98.4%. Conclusions and Relevance. Suicide prevention efforts often require rapid consolidation of evidence because of the inherent challenges of single studies trying to prevent rare outcomes. On both internal and external validation sets, ScreenAgent identified nearly all eligible studies with human-level reliability for a fraction of a US cent per record while keeping human reviewers as the final arbiters. By making broad searches feasible and screening performance measurable beforehand, this approach can serve as a transparent methodology to strengthen the speed at which we can inform and advance suicide prevention efforts.

Read PDF

Similar papers

Review Open access Jul 2026

Scoping evidence review on the prevention and treatment of opioid overdose.

Findings support future international guidelines, such as those of the WHO, to examine the effectiveness of take-home naloxone, peer training, and community-based distribution models, higher-dose naloxone protocols for ultrapotent opioids, and digital delivery models.

Abhishek Ghosh, Shinjini Choudhury, Tathagata Mahintamani et al. · 0 citations
Review Open access Aug 2026

Uncovering Means Restriction Activities for Suicide Prevention That Have Been Undertaken in Australia: A Scoping Review.

OBJECTIVES To map and summarize evidence on means restriction activities that have been implemented for the prevention of suicide across Australia. Further, to provide an overview of the impact of the activities on suicide rates and ascertain barriers/challenges, costs, and any other relevant associated information....

Julia Teng Jia Ru, David Castle, Myles N Moore et al. · 0 citations
Review Open access Aug 2026

Cancer prevention and screening for people with intellectual disabilities in Europe: a systematic review and recommendations for policy and practice

Policy guidance for cancer prevention and screening for people with intellectual disability is unevenly distributed across Europe and con centrated in a small group of countries, and EU coordination may help address this gap.

V. Vuković, Peter Knapp, Kate Sykes et al. · 0 citations
#software testing Review Open access Aug 2026

Proof of Concept of Large Language Models for Opioid Treatment Policy Surveillance: 97% Agreement With Subject Matter Experts.

LLMs could serve as a quality control check during opioid policy surveillance research, supplementing human review, and benefit from best practices and technical guidelines for LLM utilization.

B. Andraka-Christou, Jae Park, F. Ahmed et al. · 0 citations
Review Open access Jul 2026

Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis

Moderate to high certainty evidence supports discontinuation of drugs for adults with overweight or obesity because of adverse events to be highest with orforglipron, naltrexone-bupropion, liraglutide, phentermine-topiramate, CagriSema, and oral semaglutide.

Kai-Lei Nong, Qingyang Shi, Xinran Xie et al. · 5 citations
Review Open access 2026

The use of AI scribes across medical fields and why psychiatry is lagging behind: A scoping review.

This scoping review aimed to examine the current available literature on the use of artificial intelligence (AI) scribes across all medical fields compared to their use in psychiatry, finding a significant gap in the literature.

Chloé Daignault, Justine Audelin-Rinfret, M. Désilets et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.